A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

NCT00090220 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3819

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Female Participants
Prevention
Papillomavirus Infection
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Interventions

BIOLOGICAL: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
BIOLOGICAL: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC